On October 12, 2025, MGI Tech disclosed that its wholly-owned subsidiaries, MGI US LLC and Complete Genomics, Inc., had entered into a licensing agreement with Swiss Rockets AG. This agreement grants Swiss Rockets a paid license for the CoolMPS sequencing technology and general sequencing technology (encompassing underlying technologies like stLFR and cLFR).

Outside the Asia - Pacific and Greater China regions, Swiss Rockets is set to acquire an exclusive license for patents, technical know - how, and trademarks associated with the CoolMPS sequencing technology. Additionally, it will obtain a non - exclusive license for general sequencing technology, with both licenses being confined to the CoolMPS product domain.

In terms of responsibilities, MGI US LLC and Complete Genomics, Inc. will take charge of technology transfer, product development, and commercialization support. On the other hand, Swiss Rockets will be in charge of product development and commercialization within its scope.

As per the agreement, MGI Tech anticipates receiving licensing fees of no less than US$120 million. This amount includes an upfront payment of US$20 million, milestone payments totaling US$20 million, and sales royalties.